What is the downside for Amphastar Pharmaceuticals (AMPH) stock?
According to analysts' consensus price target of $23.67, Amphastar Pharmaceuticals has a forecasted downside of 4.4% from its current price of $24.75. Amphastar Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.
Where is Amphastar Pharmaceuticals located?
Amphastar Pharmaceuticals is headquartered at 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. How can I contact Amphastar Pharmaceuticals?
Who sold AMPH stock in the last quarter?
AMPH stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Nordea Investment Management AB, Frontier Capital Management Co. LLC, and State of Alaska Department of Revenue.
Did Amphastar's CFO make a large buy and sell?
William J Peters, CFO at Amphastar Pharmaceuticals (NASDAQ:AMPH), made a large buy and sell of company shares on November 11, according to a new SEC filing.
Should I buy or sell Amphastar Pharmaceuticals stock right now?
3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 1...
What is Amphastar Pharmaceuticals' stock price forecast for 2022?
3 Wall Street research analysts have issued 12-month price targets for Amphastar Pharmaceuticals' shares. Their forecasts range from $32.00 to $43....
How has Amphastar Pharmaceuticals' stock performed in 2022?
Amphastar Pharmaceuticals' stock was trading at $23.29 at the beginning of the year. Since then, AMPH stock has increased by 28.9% and is now tradi...
When is Amphastar Pharmaceuticals' next earnings date?
Amphastar Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast...
How were Amphastar Pharmaceuticals' earnings last quarter?
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) issued its earnings results on Tuesday, May, 10th. The company reported $0.47 earnings per share for...
Who are Amphastar Pharmaceuticals' key executives?
Amphastar Pharmaceuticals' management team includes the following people: Dr. Ziping Luo Ph.D. , Chairman, Chief Scientist & COO (Age 72, Pay $1...
What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?
27 employees have rated Amphastar Pharmaceuticals CEO Jack Y. Zhang on Glassdoor.com . Jack Y. Zhang has an approval rating of 35% among Amphastar...
Who are some of Amphastar Pharmaceuticals' key competitors?
Some companies that are related to Amphastar Pharmaceuticals include Perrigo (PRGO) , Intra-Cellular Therapies (ITCI) , Ionis Pharmaceuticals (I...
What other stocks do shareholders of Amphastar Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Thera...
What is the NASDAQ symbol for Amphastar?
What is Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."
Does Amphastar pay dividends?
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
What is Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals does not currently pay a dividend.
Is Amphastar Pharmaceuticals a listed company?
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as manufactures and distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors’ offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Is Amphastar a stock?
Amphastar Pharmaceuticals, Inc. is listed on the NASDAQ as ( NASDAQ:AMPH).
Is AMPH bullish?
Amphastar Pharmaceuticals, Inc. is currently listed on NASDAQ under AMPH. One share of AMPH stock can currently be purchased for approximately $ 21.14.
Does AMPH pay dividends?
6 analysts have issued ratings. Wall Street analysts rate AMPH as Bullish on average, for a Wall Street consensus of buy. View AMPH’s ratings here.
Is AMPH bullish or bearish?
AMPH does not currently pay a dividend.
What is Amphastar Pharmaceuticals?
Currently, 2 Wall Street analysts rated AMPH as Bullish, while 0 were Bearish, and 4 rated it Neutral. This suggests a consensus of AMPH going up. View AMPH’s ratings here.
What is market cap?
Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable and inhalation products. The business activities are operated through two reportable segments namely Finished pharmaceutical products and API products. The Finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, naloxone, lidocaine, as well as various other crit
Does market cap include convertible securities?
Market Cap (Capitalization) is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements.